PDCD1 and hepatocellular carcinoma: Subsequently, they followed up 10 HCC patients who received immunotherapy (PD-1 blockade), and found that 5 patients with PD-L1+ CTCs had a good response to immunotherapy, and only 1 of 5 non-responders had PD-L1+ CTCs.